BACKGROUND: The most frequent chemotherapeutic regimens used in children's cancer contain anthracyclines, which may have potentially cardiotoxic effects even at a later point in time. Echocardiography including tissue Doppler imaging is well-proved noninvasive method to assess cardiac function. OBJECTIVES: To assess the late cardiotoxic effects in young adults treated for various cancer types in childhood. METHODS: Ninety-eight young adults who were treated for childhood cancer (CCS), median time 12.1 years after finishing the therapy, were comprised into study. All subjects underwent echocardiographic examination including tissue Doppler imaging. The echocardiographic parameters were compared to 57 healthy age-matched subjects. The CCS group also underwent 24-h ECG Holter monitoring to reveal any arrhythmias. RESULTS: The subjects in CCS group had lower E′ velocities from lateral (15.6 vs. 17.6 cm/s) and septal part (12.2 vs. 14.4 cm/s) of mitral annulus (p for both <0.001) and also lower S′ velocity from the tricuspid annulus (12.4. vs. 13.3 cm/s, p = 0.013) and tricuspid annulus peak systolic excursion (TAPSE; 22.2 vs. 23.9 mm, p = 0.017). There were no significant differences in left ventricular systolic velocities or ejection fraction. The occurrence of arrhythmias did not differ among subgroups of CCS with or without anthracycline therapy. CONCLUSION: Childhood cancer survivors had subclinical cardiac impairment in comparison with healthy controls, particularly in left ventricular diastolic function.

Graphical AbstractThe aim was to assess the late cardiotoxic effects in young adults treated for various cancer types in childhood using echocardiography and 24-h ECG Holter monitoring.

Department of Children's Oncology University Hospital Brno Masaryk University Brno Czech Republic

Department of Internal Medicine Cardiology St Anne's University Hospital Faculty of Medicine Masaryk University Brno Czech Republic

Department of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech Republic

International Clinical Research Center St Anne's University Hospital Brno Czech Republic

Zobrazit více v PubMed

Lipshultz SE, Adams MJ, Colan SD, et al. Long‐term cardiovascular toxicity in children, adolescents, and young adults who receivecancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: ascientific statement from the American Heart Association. Circulation. 2013;128:1927‐1995. PubMed

Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94:525‐533. PubMed

van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. Eur J Cancer. 2006;42:3191‐3198. PubMed

Rathe M, Carlsen NL, Oxhoj H, Nielsen G. Long‐term cardiac follow‐up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54:444‐448. PubMed

Ness KK, Armenian SH, Kadan‐Lottick N, Gurney JG. Adverse effects of treatment in childhood acutelymphoblastic leukemia: general overview and implications for long‐term cardiac health. Expert Rev Hematol. 2011;4:185‐197. PubMed PMC

Lopez‐Mitnik G, Somarriba G, Lipsitz SR, et al. Exercise capacity in long‐term survivors of pediatric cancer an analysis from the cardiac risk factors in childhoodcancer survivors study. Pediatr Blood Cancer. 2013;60:663‐668. PubMed

Tonorezos ES, Snell PG, Moskowitz CS, et al. Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60:1358‐1364. PubMed PMC

De Caro E, Smeraldi A, Trocchio G, Calevo M, Hanau G, Pongiglione G. Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors. Pediatr Blood Cancer. 2011;56:122‐126. PubMed

Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Surviv. 2012;6:95‐101. PubMed PMC

Brouwer CA, Gietema JA, van den Berg MP, et al. Low‐dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post‐treatment. J Cancer Surviv. 2007;1:255‐260. PubMed

Christiansen JR, Kanellopoulos A, Lund MB, et al. Impaired exercise capacity and left ventricular function in long‐term adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62(8):1437‐1443. PubMed

Benjanuwattra J, Siri‐Angkul N, Chattipakorn SC, Hattipakorn NC. Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies. Pharmacol Res. 2019;12:104542. doi:10.1016/j.phrs.2019.104542 [Epub ahead of print]. PubMed DOI

Reulen RC, Winter DL, Frobisher C, et al. Long‐term cause‐specific mortality among survivors of childhood cancer. JAMA. 2010;304:172‐179. PubMed

Brouwer CA, Postma A, Vonk JM, et al. Systolic and diastolic dysfunction in long‐term adult survivors of childhood cancer. Eur J Cancer. 2011;47:2453‐2462. PubMed

Sofia R, Melita V, De Vita A, et al. Cardiac surveillance for early detection of late subclinical cardiac dysfunction in childhood cancer survivors after anthracycline therapy. Front Oncol. 2021;14;11:624057. doi:10.3389/fonc.2021.624057. eCollection 2021 PubMed DOI PMC

Mawad W, Mertens L, Pagano JJ, et al. Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors. Eur Heart J – Cardiovasc Imag. 2021;22:435‐442. PubMed PMC

Christiansen JR, Massey R, Dalen H, et al. Right ventricular function in long‐term adult survivors of childhood lymphoma and acute lymphoblastic leukaemia. Eur Heart J Cardiovasc Imag. 2016;17:735‐741. PubMed

Armstrong GT, Oefinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673‐3680. PubMed PMC